Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo-controlled, randomized pilot study with four-month follow-up

Arzneimittelforschung. 1992 Feb;42(2):126-32.

Abstract

The results obtained in a controlled clinical trial aimed at evaluating the efficacy and tolerability of a mucolytic treatment in laryngectomized patients are described. Domiodol (Mucolitico Maggioni, CAS 61869-07-6), an organic iodinated mucolytic agent, was given at the dosage of 60 mg t.i.d. to 20 patients in the post-operative period after laryngectomy (average 2 weeks in hospital and 4 months follow-up at home). A matched series of patients received a placebo during the hospital period and no treatment after discharge. The patients receiving the active treatment showed a statistically and clinically significant improvement of respiratory parameters (cough intensity, sputum quantity, sputum quality, expectoration difficulty). Such improvement was earlier and greater than that observed in the placebo-treated patients. It is concluded that a mucolytic treatment may be helpful in the post-operative treatment of laryngectomized patients with permanent tracheostomy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Body Temperature / drug effects
  • Cough / drug therapy
  • Dioxolanes / adverse effects
  • Dioxolanes / therapeutic use*
  • Double-Blind Method
  • Dyspnea / drug therapy
  • Expectorants / adverse effects
  • Expectorants / therapeutic use*
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Laryngectomy*
  • Male
  • Middle Aged
  • Postoperative Complications / drug therapy*
  • Sputum / cytology
  • Sputum / drug effects
  • Tracheostomy*
  • Viscosity

Substances

  • Dioxolanes
  • Expectorants
  • domiodol